Loxoribine
Structural formula | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
![]() |
|||||||||||||
General | |||||||||||||
Non-proprietary name | Loxoribine | ||||||||||||
other names |
|
||||||||||||
Molecular formula | C 13 H 17 N 5 O 6 | ||||||||||||
External identifiers / databases | |||||||||||||
|
|||||||||||||
Drug information | |||||||||||||
Drug class | |||||||||||||
properties | |||||||||||||
Molar mass | 339.30 g mol −1 | ||||||||||||
Physical state |
firmly |
||||||||||||
safety instructions | |||||||||||||
|
|||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Loxoribine is a chemical compound from the group of guanosine - nucleosides that activates toll-like receptors of type 7 (TLR 7).
properties
Loxoribine is an agonist of TLR 7 and activates the innate immune response . As a result, IFN- alpha / beta, IFN-gamma, TNF-alpha , TNF-beta , IL-1 , IL-6 and the 40 kDa chain of IL-12 are formed. Loxoribine induces the maturation of monocyte- derived dendritic cells . Alternative TLR 7 agonists are imiquimod , resiquimod and bropirimin .
Individual evidence
- ↑ a b c Sigma-Aldrich : 7-allyl-7,8-dihydro-8-oxoguanosine, 95% .
- ↑ S. Fasciano, L. Li: intervention of Toll-like receptor-mediated human innate immunity and inflammation by synthetic compounds and naturally Occurring products. In: Current medicinal chemistry. Volume 13, Number 12, 2006, pp. 1389-1395, doi : 10.2174 / 092986706776872916 , PMID 16719784 .
- ^ MG Goodman: A new approach to vaccine adjuvants. Immunopotentiation by intracellular T-helper-like signals transmitted by loxoribine. In: Pharmaceutical biotechnology. Volume 6, 1995, pp. 581-609, PMID 7551237 .
- ↑ T. Dzopalic, A. Dragicevic, S. Vasilijic, D. Vucevic, I. Majstorovic, B. Bozic, B. Balint, M. Colic: Loxoribine, a selective Toll-like receptor 7 agonist, induces maturation of human monocyte- derived dendritic cells and stimulates their Th-1 and Th-17 polarizing capability. In: International Immunopharmacology . Volume 10, number 11, November 2010, pp. 1428-1433, doi : 10.1016 / j.intimp.2010.08.010 , PMID 20817120 .